Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 6, 2009Company updates third quarter financial results and full-year 2009 guidance
Boston Scientific Corporation (NYSE: BSX) today announced that it has reached an agreement in principle with the U.S. Department of Justice (DOJ)...
-
Nov 2, 2009Third-generation drug-eluting stent now available in CE Mark countries
Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark for its PROMUS® Element™ Everolimus-Eluting Coronary Stent...
-
Oct 19, 2009
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2009, as well as guidance for...
-
Oct 9, 2009
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30,...
-
Oct 6, 2009Three models of stenting system now available for palliative treatment of malignant common bile duct strictures
Boston Scientific Corporation (NYSE: BSX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to...
-
Oct 5, 2009
Boston Scientific Corporation (NYSE: BSX) today announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial. This new...
-
Sep 29, 2009
Boston Scientific Corporation (NYSE: BSX) today announced the settlement of more than a dozen lawsuits involving Johnson & Johnson, including the...
-
Sep 25, 2009
Boston Scientific Corporation (NYSE: BSX) today announced two-year follow-up data from the HORIZONS-AMI trial. The trial,...
-
Sep 23, 2009Results support benefits of paclitaxel-eluting stents in diabetic patients
Boston Scientific Corporation (NYSE: BSX) today welcomed one-year data from the SPIRIT IV clinical trial comparing the XIENCE...
-
Sep 22, 2009Three-year TAXUS ATLAS results show safety and efficacy advantages for Boston Scientific TAXUS Liberte Stent
Boston Scientific Corporation (NYSE: BSX) today announced comprehensive data from the TAXUS ATLAS clinical program, a series of...